Optimer Pharmaceuticals, Inc. (OPTR) – StreetInsider.com Reports
-
UPDATE: Optimer Pharma (OPTR) Halted for Information (CBST)
-
Cubist Pharma (CBST), Optimer (OPTR) Report Expiration of HSR Act in Proposed Merger
-
Cubist Pharma (CBST) Announces $600M Convertible Notes Offering
-
Optimer Pharmaceuticals (OPTR) Tops Q2 EPS by 7c
-
Trading Radar for 08/01: Exxon (XOM), Chesapeake (CHK), P&G (PG), Activision (ATVI) Report
-
Jefferies Raises PT on Cubist Pharmaceuticals (CBST) to $70
-
Notable Mergers and Acquisitions of the Day 07/31: (BRE) (KKR) (ACN)/(BAH) (CBST)
-
Streetinsider.com Pre-Open Movers 07/31: (TSRX) (QCOR) (AEGR) Higher; (JIVE) (RVBD) (BGFV) Lower (more...)
-
Jefferies Downgrades Optimer Pharmaceuticals (OPTR) to Hold
-
Canaccord Genuity Downgrades Optimer Pharmaceuticals (OPTR) to Hold
-
Goldman Cuts Cubist Pharmaceuticals (CBST) to Neutral, Concerned about Execution
-
Streetinsider.com After-Hours Movers 07/30: (TSRX) (QCOR) (SYMC) Higher; (JIVE) (RVBD) (BGFV) Lower (more...)
-
Market Wrap: Confidence Slips from Multi-Year Highs; Facebook Pushes Games; Mergers in Health-Ville
-
Optimer’s (OPTR) Posts Prelim. Q2 Loss of 55c/Share, Beats Views
-
Cubist (CBST) to Acquire Optimer (OPTR) for $10.75/Share
-
Cubist (CBST) Said to Bid $1B for Optimer (OPTR) Before Sales Proceeds - Reuters
-
Market Wrap: Retail Sales Rip in April; Theravance, Elan Enter $1B Deal; Petrobras' Record Debt Sale
-
Optimer (OPTR) Names Eric Sirota as COO
-
Optimer Pharmaceuticals (OPTR) Jumps as AstraZeneca (AZN), Cubist (CBST) Submit First Round Bids
-
Baird Downgrades Optimer Pharmaceuticals (OPTR) to Neutral
-
Needham & Company Downgrades Optimer Pharmaceuticals (OPTR) to Hold on Weaker Dificid Sales; Says Takeover Hopes Dim
-
Optimer Pharmaceuticals (OPTR) Misses Q1 EPS by 23c
-
Trading Radar for 05/09: priceline.com (PCLN), NVIDIA (NVDA), DISH Network (DISH), Dean Foods (DF) Report
-
Cantor Fitzgerald Downgrades Cubist Pharmaceuticals (CBST) to Sell; Doesn't See Deal for Optimer (OPTR)
-
Unusual 11 Mid-Day Movers 04/02: (BGCP) (OPTR) (EHTH) Higher; (IGOI) (SARA) (NDAQ) Lower
-
Optimer Pharma (OPTR) Said to Draw Interest from Glaxo (GSK), Astellas
-
JMP Securities Downgrades Optimer Pharmaceuticals (OPTR) to Market Perform
-
Optimer Pharmaceuticals (OPTR) Posts Q2 Profit of $0.02/Sh
-
Trading Radar for 02/28: Kohls (KSS), salesforce.com (CRM), Gap (GPS), Cablevision (CVC), Palo Alto Networks (PANW) Report
-
Baird Starts Optimer Pharmaceuticals (OPTR) at Outperform, $16 PT
-
Optimer Pharma (OPTR) Discloses 12,080 RSU Inducement Award
-
Optimer Pharmaceuticals (OPTR) Tops Q3 EPS by 8c
-
Jefferies Keeps Optimer (OPTR) at Buy as CEO Makes Plans For Growth
-
UPDATE: Oppenheimer Downgrades Optimer Pharmaceuticals (OPTR) to Perform, Questions About Near-Term Growth
-
Optimer Pharmaceuticals (OPTR) to Sell Remaining Ownership in Optimer Biotechnology for $60M
-
Morgan Stanley Starts Optimer Pharmaceuticals (OPTR) at Underweight
-
Leerink Swann Starts Optimer Pharmaceuticals (OPTR) at Outperform
-
BofA/Merrill Lynch Downgrades Optimer Pharmaceuticals (OPTR) Two-Notches to Underperform
-
Needham & Company reiterates a 'Buy' on Optimer Pharmaceuticals (OPTR); Generic Vancomycin in U.S. Appears to have Minimal Impact
-
Needham & Company Reiterates a 'Buy' on Optimer Pharmaceuticals (OPTR); Raising Q4 on Dificid Use in Medicare In-Patient Cases
-
Optimer (OPTR) Announces Add-on Payment From Medicare & Medicaid Services for its DIFICID
-
Baird Maintains an 'Outperform' on Optimer Pharmaceuticals (OPTR); Staying Put Despite Q2 Disappointment
-
Canaccord Genuity on Optimer Pharmaceuticals (OPTR): June Blip, But Trends Remain Strong & Doctors Are Interested
-
Needham & Company Defends on Optimer (OPTR); Favorable Long-Term Trend Intact
-
After-Hours Movers 07/31: (SIMG) (DEPO) (MRGE) Higher; (CECO) (PPO) (DRIV) Lower
-
Optimer Pharmaceuticals (OPTR) Misses Q2 EPS by 6c
-
Trading Radar for 07/31: US Steel (X), Coach (COH), Electronic Arts (EA), UBS AG (UBS), Goodyear(GT) Report
-
Needham & Company Maintains a 'Buy' on Optimer Pharmaceuticals (OPTR); Q2 Preview
-
Canaccord Genuity Assumes Coverage on Optimer Pharmaceuticals (OPTR) at Buy; Near Term Growth Driven by Unmet Need
-
Optimer Pharma (OPTR) Gets Health Canada Approval for DIFICID Tabs as CDI Treatment
Back to OPTR Stock Lookup